Skip to Content
COVID-19 Response and Update
International
  • About
        • AboutWe challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Program
          • Product Donations
          • National and Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • ProductsWe create essential medicines
        • Our Portfolio
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & DevelopmentWe invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • InvestorsBecome an Informed Investor
        • Financial Reports
          • SEC Filings
          • Annual Reports
          • Quarterly & Other Reports
        • Events & Presentations
        • Stock Information
        • Corporate Governance
          • Policies
          • Executive Officers & Directors
          • Board Committees
        • Investor Resources
          • Analysts
          • Investor FAQ
          • Email Alerts
          • Information Request
          • RSS Feeds
  • News
  • Careers
        • CareersHelp make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals

Research & Development

We invest significantly in new product development

Our R&D strategy is led by a world-class in-house development team and supplemented by creative product development partnerships with external stakeholders. The focus of our R&D strategies is ensuring the ongoing innovation of important and value-generating products across our portfolios.

A proven track record of innovation for patients

The graphic below reflects the timing of when a new product in each dosage form category was initially launched by Amneal or is expected to launch.
2002: Amneal Founded - 2005: Oral Solids - 2008: Oral Liquids - 2011: Topicals - 2015: Inserts/Implants, Inhalation - 2016: Injectables - 2017: Nasal Sprays - 2019: Transdermal Patches - 2020: Ophthalmics - 2022: LYVISPAH™ - 2022: DHE Autoinjector - 2022: Biosimilars - 2023: International Expansion, IPX-203 - 2023-2024: K-127 - 2024-2025: K-114

*Data as of January 2022

Learn more about our Specialty R&D pipeline here

Learn more about our R&D capabilities:

Generics R&D
Generics R&D
Specialty R&D
Specialty R&D
Product Partnering
Product Partnering
  • Privacy Notice
  • Copyright & Legal Disclaimer
  • Web Accessibility
  • NABP DDA Accreditation
  • Linkedin
  • Twitter
  • Youtube
© 2022 Amneal Pharmaceuticals LLC.
All rights reserved.